A brief guide to the use of giritinib (segatan)

Giritinib (trade name: Segatan), as a targeted therapy for acute myeloid leukemia (AML) carryingFMS-like tyrosine kinase 3 (FLT3) mutations, has brought new treatment hope to many patients. To ensure patients can use giritinib safely and effectively, the following is a concise guide to its use.

1. Applicable people

Giritinib is indicated for adult patients with relapsed or refractory AML confirmed by a well-validated test method to carryFLT3 mutations. Before use, patients should undergo genetic testing to confirm whether they are suitable for treatment with this drug.

2. Usage and dosage

1. Dosage: The recommended starting dose of gilitinib is 120 milligrams (mg) per day, that is, three 40 mg tablets, once daily. In the absence of disease progression or unacceptable toxicity, treatment is recommended for at least 6 months to allow time for clinical response. Do not change your dose or stop taking this medicine without your doctor's advice.

2. How to take: Giritinib should be taken whole with water and should not be broken or crushed. Patients can take it with or without food, but it is recommended to take it at the same time every day to maintain stable blood levels.

3. Handling of missed doses: If you miss a dose, you should take it as soon as you remember. However, if it is less than 12 hours before the next dose, skip the missed dose and take the next dose at the originally planned time.

3. Precautions

1. Gene testing: FLT3 gene testing must be performed before use to confirm whether the patient carries the mutation.

2. Monitoring indicators: Blood cell counts, blood biochemical indicators and electrocardiogram should be monitored regularly during treatment to detect and deal with possible adverse reactions in a timely manner.

3. Special groups: Pregnant and lactating women should avoid using gilitinib, or use it with caution under the guidance of a doctor. Women of childbearing potential should use effective contraceptive measures during treatment.

4. Drug interactions: Giritinib is mainly metabolized byCYP3A4 enzyme. It should be avoided to be used in combination with strong CYP3A/P-glycoprotein inducers or inhibitors to avoid drug interactions.

5. Storage conditions: Store this medication in its original container at room temperature, away from moisture and heat.

4. Adverse reactions

Giritinib may cause a series of adverse reactions, including but not limited to muscle or joint pain, headache, dizziness, fever, fatigue, abnormal liver function tests, and differentiation syndrome. Patients should pay close attention to their own symptoms during use and seek medical attention promptly if any abnormalities occur.

In summary, gilitinib is an effective treatment for selectAML patients. Patients should fully understand its indications, usage, dosage and precautions before use, and use it rationally under the guidance of a doctor to ensure the safety and effectiveness of treatment. Currently, giritinib has both original drugs and affordable generic drugs for sale. Patients should choose according to their needs, but be sure to purchase through formal channels.